Skip to content

Efficacy of thermostatic moxibustion for the patients with cancer-related fatigue in colon cancer: a randomized controlled trial

Efficacy of thermostatic moxibustion for the patients with cancer-related fatigue in colon cancer: a randomized controlled trial

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Interventional
Source
ITMCTR
Registry ID
ITMCTR2200006041
Enrollment
Unknown
Registered
2022-05-27
Start date
2022-06-01
Completion date
Unknown
Last updated
2023-02-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

colon cancer

Interventions

Moxibustion of 45°C ± 1°C Constant Temperature Group:Moxibustion
Conventional Moxibustion Group:Moxibustion
Routine Nursing Group:routine treatment and care

Sponsors

Third Affiliated People's Hospital of Fujian University of Traditional Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
40 Years to 75 Years

Inclusion criteria

Inclusion criteria: (1)Male or female aged from 40 to 75 years old; (2)Had undergone radical?operation?for?carcinoma?of?colon and was in the chemotherapy stage. The operation and chemotherapy regimen was not limited; (3)Fulfilment of the diagnostic criteria for CRF of the international classification of diseases, tenth revision clinical modification (ICD-10); (4)The physical condition was according to Karnofsky (KPS) score of 60 or more; (5)Willingness to participate in the trial and having provided written consent.

Exclusion criteria

Exclusion criteria: (1)Those who have participated in any other clinical trials to mitigate CRF except this trial; (2)Patients with skin lesions and damaged skin at the site of operation; (3)Complicated with severe cardiovascular and cerebrovascular diseases; (4)Allergic to moxa, patients with allergic respiratory diseases; (5)Patients with inability to cooperate with mental illness; (6)Patients with fatigue-related diseases (hypothyroidism, severe anemia, autoimmune disease, abnormal liver or kidney function test (aspartate aminotransferase or alanine aminotransferase =2 x upper limit of normal or creatinine=2.0 mg/dL)); (7) An estimated life expectancy of six months or less.

Design outcomes

Primary

MeasureTime frame
The Chinese version of the Brief Fatigue Inventory (BFI-C);

Secondary

MeasureTime frame
Laboratory examination;TCM syndrome scores;The Fuzhou version of the Montreal Cognitive Assessment (MoCA-fuzhou);Adverse events;EORTC QLQ-C30;

Countries

China

Contacts

Public ContactYang Liu
94493607@qq.com+8613959148480

Outcome results

None listed

Source: ITMCTR (via WHO ICTRP) · Data processed: Feb 4, 2026